期刊文献+

Associations of pharmaceutical and personal care product chemical exposure with thyroid nodules and thyroid homeostasis

原文传递
导出
摘要 Pharmaceuticals and personal care products(PPCPs)have been considered as potential contributors to thyroid nodule(TN)and abnormal thyroid homeostasis,but epidemiological evidence is scarce.A total of 1261 individuals comprised of 367 TN patients and 895 controls were recruited from Sichuan,China.The urinary concentrations of fourteen PPCPs were measured.Five thyroid hormones(THs)in serum were determined as indicators of thyroid homeostasis,including thyroid-stimulating hormone,triiodothyronine(T3),thyroxine(T4),free-T3 and free-T4.Serum levels of thyroglobulin antibody(TGAb)and thyroperoxidase antibody(TPOAb)were quantified to identify individual thyroid antibody(TA)statuses.TN patients exhibited higher propyl-paraben(PrP)(median:1.30μg/g Cr)level than controls(0.64μg/g Cr).PrP were significantly associated with TN risk with ORs of 1.060(95%CI:1.002,1.122).The relationship of methyl-paraben with TN risk was nonlinear(p=0.049).PPCP exposurewas significantwith TN risk only in females and TA positive(TPOAb or TGAb)groups,indicating that PPCP susceptibility to TN differs by sex and TA status.Linear regression models showed ethyl-paraben was significantly negatively associated with T4(β:-0.005,95%CI:-0.011,-0.002)and T3(β:-0.007,95%CI:-0.015,-0.002),and positively associated with TPOAb(β:0.059,95%CI:0.000,0.119),suggesting that certain PPCP exposure could affect thyroid homeostasis and autoimmunity.The effects of PPCP exposure on TH and TA levels presented sex-specific.Our findings suggest that PPCP exposure increases TN risk and affects thyroid homeostasis,exhibiting sex and antibody status dependence.
出处 《Journal of Environmental Sciences》 2025年第11期21-34,共14页 环境科学学报(英文版)
基金 supported by the National Natural Science Foundation of China(Nos.21976046 and 42177412) the Ministry of Education of China(No.B17025).
  • 相关文献

参考文献1

二级参考文献90

  • 1Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006; 58: 685- 704.
  • 2Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004; 3: 950-64.
  • 3Rastinejad F, Huang P, Chandra V, Khorasanizadeh S. Understanding nuclear receptor form and function using structural biology. J Mol Endocrinol 2013; 51: T1-T21.
  • 4Li Y, Lambert MH, Xu HE. Activation of nuclear receptors: a per- spective from structural genomics. Structure 2003; 11: 741-6.
  • 5Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand- binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000; 21: 381-8.
  • 6Hughes TS, Chalmers M J, Novick S, Kuruvilla DS, Chang MR, Kamenecka TM, et al. Ligand and receptor dynamics contribute to the mechanism of graded PPARgamma agonism. Structure 2011; 20: 139-50.
  • 7Nettles KW, Greene GL. Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol 2005; 67: 309-33.
  • 8Nahoum V, Perez E, Germain P, Rodriguez-Barrios F, Manzo F, Kammerer S, et al. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc Natl Acad Sci U S A 2007; 104: 17323-8.
  • 9BourguetW, de Lera AR, Gronemeyer H. Inverse agonists and antagonists of retinoid receptors. Methods Enzymol 2010; 485: 161-95.
  • 10Germain P, Gaudon C, Pogenberg V, Sanglier S, Van Dorsselaer A, Royer CA, et al. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem Biol 2009; 16: 479-89.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部